AURIGENE PHARMACEUTICAL SERVICES LIMITED
Aurigene Pharmaceutical Services Limited, commonly referred to as Aurigene, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 2001, the company has made significant strides in drug discovery and development, focusing on oncology and autoimmune diseases. With a strong operational presence across major regions, Aurigene has built a reputation for its innovative approach to biopharmaceuticals. The company offers a range of services, including preclinical and clinical development, which are distinguished by their commitment to quality and scientific excellence. Aurigene's unique capabilities in small molecule drug discovery have positioned it as a trusted partner for global pharmaceutical companies. Notable achievements include successful collaborations and advancements in targeted therapies, solidifying its market position as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does AURIGENE PHARMACEUTICAL SERVICES LIMITED's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AURIGENE PHARMACEUTICAL SERVICES LIMITED's score of 1 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AURIGENE PHARMACEUTICAL SERVICES LIMITED's reported carbon emissions
In 2022, AURIGENE PHARMACEUTICAL SERVICES LIMITED reported total carbon emissions of approximately 302,466,000 kg CO2e for Scope 1, 166,247,000 kg CO2e for Scope 2, and 470,262,000 kg CO2e for Scope 3. This reflects a continued commitment to monitoring and managing their carbon footprint across all scopes of emissions. Over the previous years, the company has shown fluctuations in emissions, with Scope 1 emissions decreasing from about 364,283,000 kg CO2e in 2019 to 302,466,000 kg CO2e in 2022. Similarly, Scope 2 emissions have also seen a reduction from approximately 178,480,000 kg CO2e in 2019 to 166,247,000 kg CO2e in 2022. However, Scope 3 emissions increased from about 331,501,000 kg CO2e in 2019 to 470,262,000 kg CO2e in 2022, indicating a need for further focus on upstream and downstream emissions. Despite these figures, AURIGENE PHARMACEUTICAL SERVICES LIMITED has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. This suggests that while the company is actively tracking its emissions, it may benefit from establishing formal commitments to further enhance its climate strategy and reduce its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 364,283,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 178,480,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 331,501,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AURIGENE PHARMACEUTICAL SERVICES LIMITED is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
